Abstract

Childhood asthma develops in 30–40% of children with severe bronchiolitis but accurate prediction remains challenging. In a severe bronchiolitis cohort, we applied the Asthma Predictive Index (API), the modified Asthma Predictive Index (mAPI), and the Pediatric Asthma Risk Score (PARS) to predict asthma at age 5 years. We applied the API, mAPI, and PARS to the 17-center cohort of infants hospitalized with severe bronchiolitis during 2011–2014 (35th Multicenter Airway Research Collaboration, MARC-35). We used data from the first 3 years of life including parent interviews, chart review, and specific IgE testing to predict asthma at age 5 years, defined as parent report of clinician-diagnosed asthma. Among 875/921 (95%) children with outcome data, parent-reported asthma was 294/875 (34%). In MARC-35, a positive index/score for stringent and loose API, mAPI, and PARS were 24, 68, 6, and 55%, respectively. The prediction tools' AUCs (95%CI) ranged from 0.57 (95%CI 0.54–0.59) to 0.68 (95%CI 0.65–0.71). The positive likelihood ratios were lower in MARC-35 compared to the published results from the original cohorts. In this high-risk population of infants hospitalized with severe bronchiolitis, API, mAPI, and PARS had sub-optimal performance (AUC <0.8). Highly accurate (AUC >0.8) asthma prediction tools are desired in infants hospitalized with severe bronchiolitis.

Highlights

  • Asthma is a chronic inflammatory airway condition affecting ∼8% of US children [1] and is projected to cost over $300 billion from 2018 to 2038 [2]

  • We investigated the prediction performance of Asthma Predictive Index (API), modified Asthma Predictive Index (mAPI), and Pediatric Asthma Risk Score (PARS) in our prospective cohort of children hospitalized with severe bronchiolitis, using data from infancy to age 3 years to predict asthma development at age 5 years

  • We analyzed data from the 35th Multicenter Airway Research Collaboration (MARC-35), a multi-center, prospective cohort of infants hospitalized for bronchiolitis

Read more

Summary

Introduction

Asthma is a chronic inflammatory airway condition affecting ∼8% of US children [1] and is projected to cost over $300 billion from 2018 to 2038 [2]. Asthma pathobiology is incompletely understood [3,4,5]. Childhood asthma development often precedes recurrent or severe asthma-like symptoms, especially wheezing [6,7,8,9]. Bronchiolitis is the leading cause of US infants’ hospitalization [7, 9, 10]. Among these infants, ∼30-40% will develop childhood asthma [7, 10,11,12,13]. The accurate identification of those at higher risk is important to optimize preventive strategies and treatment

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call